Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Thorac Cancer. 2021 Mar;12(6):760-767. doi: 10.1111/1759-7714.13835. Epub 2021 Jan 22.
Currently, there is no consensus on the role of postoperative adjuvant radiotherapy (PORT) for resected stage IIIA/N2 non-small cell lung cancer (NSCLC). Our study sought to determine which patients may be able to benefit from PORT, based on a patient prognostic score.
A retrospective cohort study was conducted to identify patients diagnosed with IIIA/N2 NSCLC between 1988 and 2016 in the SEER database. Eligible patients were divided into the following two groups: PORT group and non-PORT group. We classified patient prognostic scores as an ordinal factor and stratified patients based on prognostic scores. A Cox proportional hazards model with propensity score weighting was performed to evaluate cancer-specific mortality (CSM) between the two groups.
We identified 7060 eligible patients with IIIA/N2 NSCLC, 2833 (40.1%) in the PORT group and 4227 (59.9%) in the non-PORT group. Overall, the 10-year CSM rate in the weighted cohorts was 70.4% in the PORT group, 72.0% in the non-PORT group, and patients who received PORT had a lower CSM rate (p = 0.001). Compared with the non-PORT group, significant survival improvements in the PORT group were observed in patients with higher age, grade, T stage and lymph node ratio (LNR), and without chemotherapy. The improved survival of patients receiving PORT was significantly correlated with patient prognostic scores (p < 0.001).
In our population-based study, the prognostic score was associated with the survival improvement offered by PORT in IIIA/N2 NSCLC, suggesting that prognostic scores and clinicopathological characteristics may be helpful in proper candidate selection for PORT.
目前,对于接受手术治疗的 IIIA/N2 期非小细胞肺癌(NSCLC)患者,术后辅助放疗(PORT)的作用尚未达成共识。本研究旨在基于患者预后评分,确定哪些患者可能从 PORT 中获益。
本研究采用回顾性队列研究,从 SEER 数据库中筛选 1988 年至 2016 年间诊断为 IIIA/N2 NSCLC 的患者。符合条件的患者被分为 PORT 组和非 PORT 组。我们将患者预后评分归类为有序因素,并根据预后评分对患者进行分层。采用倾向评分加权的 Cox 比例风险模型评估两组间的癌症特异性死亡率(CSM)。
共纳入 7060 例 IIIA/N2 NSCLC 患者,PORT 组 2833 例(40.1%),非 PORT 组 4227 例(59.9%)。两组患者加权后 10 年 CSM 率分别为 PORT 组 70.4%,非 PORT 组 72.0%,PORT 组 CSM 率更低(p=0.001)。与非 PORT 组相比,PORT 组中年龄较大、分级较高、T 分期和淋巴结比值(LNR)较高、未接受化疗的患者生存获益更为显著。PORT 组患者的生存获益与患者预后评分显著相关(p<0.001)。
在本基于人群的研究中,预后评分与 PORT 治疗 IIIA/N2 NSCLC 患者的生存改善相关,提示预后评分和临床病理特征可能有助于 PORT 治疗的恰当患者选择。